Genes and immune cells predict immunotherapy success in bladder cancer

Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study published in Clinical Cancer Research, the team uncovered gene signatures representing adaptive immunity and pro-tumorigenic inflammation that were responsible for sensitivity or resistance to immune checkpoint inhibitors, drugs that help the body’s immune system recognize and attack cancerous cells.

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *

The information on this site is of a general nature only and is not intended to address the specific circumstances of any particular individual or entity. It is not intended or implied to be a substitute for professional advice. Read more.